The RIO Trial has published in the Lancet
Dr Rebecca Sutherland, the Principal Investigator on The RIO Trial in CIRG, was a co-author on the article.
The RIO Trial has published an article in the Lancet showing their findings from the study.
The RIO Trial is a randomised placebo controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated Primary HIV Infection on viral control off ART.
The study aimed to demonstrate whether the combination of two long-acting (LS) broadly neutralising antibodies, 3BNC117-LS and 10-1074-LS, can keep viral load undetectable without antiretroviral treatment (ART). The study looked at how long viral load stays undetectable without ART and what happens to the HIV virus and immune system in blood samples.
Read more about the study findings in the article through the link below.
